Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Bluestem Capital by Carolyn Helms | Aug 10, 2021 | Portfolio News
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia by Carolyn Helms | Aug 10, 2021 | Portfolio News
Tricida Announces Second Quarter 2021 Financial Results by Carolyn Helms | Aug 9, 2021 | Portfolio News
Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding by Carolyn Helms | Aug 9, 2021 | Portfolio News
Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections by Carolyn Helms | Aug 5, 2021 | Portfolio News
